| 28.46 1.55 (5.76%) | 05-15 14:45 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35.55 | 1-year : | 39.12 |
| Resists | First : | 30.44 | Second : | 33.5 |
| Pivot price | 28.34 |
|||
| Supports | First : | 25.5 | Second : | 21.21 |
| MAs | MA(5) : | 27.34 |
MA(20) : | 28.34 |
| MA(100) : | 28.13 |
MA(250) : | 21.08 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.4 |
D(3) : | 24.3 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 83.59 | Low : | 7.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RGC ] has closed below upper band by 41.2%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 27.58 - 27.73 | 27.73 - 27.85 |
| Low: | 26.31 - 26.52 | 26.52 - 26.7 |
| Close: | 26.59 - 26.91 | 26.91 - 27.17 |
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Thu, 14 May 2026
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC - ChartMill
Thu, 14 May 2026
Regencell Bioscience Holdings Limited - Ordinary Shares (NQ: RGC - FinancialContent
Thu, 14 May 2026
RGC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review
Tue, 12 May 2026
RGC Deadline Alert: The Gross Law Firm Reminds Regencell Bioscie - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 494 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 88.5 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 831 (K) |
| Shares Short P.Month | 607 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -54.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -2879.99 |
| PEG Ratio | 0 |
| Price to Book value | 2879.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -4579.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|